MA46955A - Nouveaux composés en tant qu'agonistes récepteurs de glp1/glucagon/gip trigonal peptidique - Google Patents

Nouveaux composés en tant qu'agonistes récepteurs de glp1/glucagon/gip trigonal peptidique

Info

Publication number: MA46955A
Authority: MA; Morocco
Prior art keywords: peptidique; glp1; trigonal; gip; glucagon
Prior art date: 2016-12-02

Application number

MA046955A

Other languages

English (en)

Inventor

Martin Bossart

Andreas Evers

Torsten Haack

Dieter Kadereit

Katrin Lorenz

Martin Lorenz

Stefania Pfeiffer-Marek

Michael Wagner

Original Assignee

Sanofi Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-12-02

Filing date

2017-12-01

Publication date

2021-05-19

2017-12-01 Application filed by Sanofi Sa filed Critical Sanofi Sa

2021-05-19 Publication of MA46955A publication Critical patent/MA46955A/fr

Links

102000051325 Glucagon Human genes 0.000 title 1
108060003199 Glucagon Proteins 0.000 title 1
108091016366 Histone-lysine N-methyltransferase EHMT1 Proteins 0.000 title 1
102100040918 Pro-glucagon Human genes 0.000 title 1
150000001875 compounds Chemical class 0.000 title 1
MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 title 1
229960004666 glucagon Drugs 0.000 title 1
239000000018 receptor agonist Substances 0.000 title 1
229940044601 receptor agonist Drugs 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Endocrinology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Zoology (AREA)
Diabetes (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Toxicology (AREA)
Biochemistry (AREA)
Vascular Medicine (AREA)
Epidemiology (AREA)
Obesity (AREA)
Hematology (AREA)
Cardiology (AREA)
Immunology (AREA)
Emergency Medicine (AREA)
Heart & Thoracic Surgery (AREA)
Child & Adolescent Psychology (AREA)
Hospice & Palliative Care (AREA)
Urology & Nephrology (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

MA046955A 2016-12-02 2017-12-01 Nouveaux composés en tant qu'agonistes récepteurs de glp1/glucagon/gip trigonal peptidique MA46955A (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP16306604		2016-12-02

Publications (1)

Publication Number	Publication Date
MA46955A true MA46955A (fr)	2021-05-19

Family

ID=57542935

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA046955A MA46955A (fr)	2016-12-02	2017-12-01	Nouveaux composés en tant qu'agonistes récepteurs de glp1/glucagon/gip trigonal peptidique

Country Status (23)

Country	Link
US (1)	US10538567B2 (fr)
EP (1)	EP3548508B1 (fr)
JP (1)	JP7100033B2 (fr)
KR (1)	KR102576872B1 (fr)
CN (1)	CN110023329B (fr)
AR (1)	AR110300A1 (fr)
AU (1)	AU2017367173B2 (fr)
BR (1)	BR112019011228A2 (fr)
CA (1)	CA3045377A1 (fr)
CL (1)	CL2019001465A1 (fr)
CO (1)	CO2019006917A2 (fr)
CR (1)	CR20190313A (fr)
DO (1)	DOP2019000068A (fr)
EA (1)	EA201991345A1 (fr)
EC (1)	ECSP19046893A (fr)
IL (1)	IL266984A (fr)
MA (1)	MA46955A (fr)
MX (1)	MX2019006429A (fr)
PE (1)	PE20191143A1 (fr)
PH (1)	PH12019501216A1 (fr)
TW (1)	TW201833132A (fr)
UY (1)	UY37506A (fr)
WO (1)	WO2018100134A1 (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AR110300A1 (es)	2016-12-02	2019-03-13	Sanofi Sa	Compuestos como agonistas peptídicos trigonales de los receptores de glp1 / glucagón / gip
TW201833131A (zh)	2016-12-02	2018-09-16	法商賽諾菲公司	作為胜肽類ｇｌｐ１／升糖素／ｇｉｐ受體促效劑之新化合物
SG11202010017SA (en)	2018-04-10	2020-11-27	Sanofi Aventis Deutschland	Method for cleavage of solid phase-bound peptides from the solid phase
KR102727918B1 (ko)	2018-04-10	2024-11-11	사노피-아벤티스 도이칠란트 게엠베하	캡핑을 사용한 릭시세나티드 합성
UY38249A (es)	2018-05-30	2019-12-31	Sanofi Sa	Productos conjugados que comprenden un agonista del receptor triple de glp-1/glucagón/gip, un conector y ácido hialurónico
CN113453703A (zh) *	2018-12-21	2021-09-28	韩美药品株式会社	包括胰岛素和对胰高血糖素和glp-1和gip受体均具有活性的三重激动剂的药物组合物
SG11202111311WA (en)	2019-06-14	2021-12-30	Zealand Pharma As	Pharmaceutical parenteral composition of dual glp1/2 agonist
KR20210040818A (ko) *	2019-10-04	2021-04-14	한미약품 주식회사	글루카곤, 및 glp-1 수용체 및 gip 수용체 이중 작용제를 포함하는 조성물 및 이의 치료학적 용도
CR20220206A (es)	2019-11-11	2022-06-16	Boehringer Ingelheim Int	Agonistas del receptor npy2
TW202140058A (zh) *	2020-01-30	2021-11-01	美商美國禮來大藥廠	提派肽（ｔｉｒｚｅｐａｔｉｄｅ）之治療用途
JP7661478B2 (ja)	2020-08-07	2025-04-14	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	可溶性ｎｐｙ２受容体アゴニスト
WO2022034062A1 (fr) *	2020-08-12	2022-02-17	Txp Pharma Ag	Analogues peptidiques d'exendine-4
EP4197550A4 (fr) *	2020-08-14	2025-10-08	Hanmi Pharmaceutical Co Ltd	Composition pharmaceutique à effet hypotenseur comprenant un activateur triple présentant une activité pour tous les récepteurs du glucagon, de la glp-1, et de la gip
CN114349828B (zh) *	2020-11-27	2023-12-08	江苏师范大学	Glp-1/胰高血糖素受体双重激动剂及其应用
MX2023006280A (es) *	2020-12-16	2023-06-13	Zealand Pharma As	Composicion farmaceutica de agonistas duales de glp-1/glp-2.
CA3200526A1 (fr) *	2020-12-16	2022-06-23	Jesper Skodborg VILLADSEN	Composition pharmaceutique de doubles agonistes de glp-1/glp-2
IL301892A (en) *	2020-12-16	2023-06-01	Zealand Pharma As	Drug composition of dual GLP-1/GLP-2 agonists
CN117750953A (zh) *	2021-06-25	2024-03-22	伊莱利利公司	用于治疗阻塞性睡眠呼吸暂停的方法
KR20230004135A (ko) *	2021-06-30	2023-01-06	한미약품 주식회사	글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체를 포함하는 조합물의 치료학적 용도
GB2634433A (en) *	2022-05-27	2025-04-09	D&D Pharmatech Inc	Peptide compositions and methods of use thereof
AU2023348864A1 (en) *	2022-09-28	2025-03-20	Sunshine Lake Pharma Co., Ltd.	Glp-1/gcg/gip triple-receptor agonist and use thereof
IL321555B1 (en) *	2022-12-23	2026-01-01	Hanmi Pharmaceutical Co Ltd	A novel triple agonist for glp-1/gip/glucagon and a pharmaceutical preparation containing it for the prevention or treatment of obesity
WO2025049610A1 (fr) *	2023-08-28	2025-03-06	Shattuck Labs, Inc.	Peptides multi-actions
CN117586374B (zh) *	2023-10-07	2024-11-29	深圳湾实验室	Glp-1r/gipr/gcgr三重激动剂类似物及其用途
CN119241684B (zh) *	2024-11-22	2025-02-25	徐州医科大学	一种肠促胰岛素类似物及其用途
WO2026082196A1 (fr) *	2025-03-13	2026-04-23	深圳碳云智肽药物科技有限公司	Triple agoniste pour récepteurs du glp-1, du gip et du gcg et son utilisation

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BR0314996A (pt)	2002-10-02	2005-08-09	Zealand Pharma As	Composição, composição farmaceuticamente aceitável, método para produzir a composição, métodos para estabilizar a exendina-4 (1-39) ou uma sua variante, derivado ou análogo contra a degradação, antes, durante ou após o uso pretendido, para tratar doenças, para tratar de estados de doenças associados com nìveis elevados de glicose do sangue, para a regulação dos nìveis de glicose do sangue, para a regulação do esvaziamento gástrico, para estimular a liberação de insulina em um mamìfero para reduzir o nìvel de glicose do sangue em um mamìfero, para reduzir o nìvel de lipìdeos plasmáticos em um mamìfero, para reduzir a mortalidade e a morbidez após o infarto miocárdico em um mamìfero, para estimular a liberação de insulina em um mamìfero, e para produzir uma exendina (1-39) estabilizada, e, exendina (1-39) estabilizada
US20080019911A1 (en) *	2005-04-20	2008-01-24	Aimin Xu	Method for decreasing blood glucose and improving glucose tolerance using angiopoietin-like protein 4
ATE553124T1 (de)	2005-06-13	2012-04-15	Imp Innovations Ltd	Oxyntomodulinanaloga und ihre wirkungen auf das fressverhalten
CN102105159B (zh)	2008-06-17	2015-07-08	印第安纳大学研究及科技有限公司	基于gip的混合激动剂用于治疗代谢紊乱和肥胖症
EP2443146B1 (fr)	2009-06-16	2016-10-05	Indiana University Research And Technology Corporation	Composés de glucagon actifs sur le récepteur gip
US20120148586A1 (en) *	2009-08-27	2012-06-14	Joyce Ching Tsu Chou	Glucagon-like protein-1 receptor (glp-1r) agonists for treating autoimmune disorders
AU2011202239C1 (en)	2010-05-19	2017-03-16	Sanofi	Long-acting formulations of insulins
US8507428B2 (en)	2010-12-22	2013-08-13	Indiana University Research And Technology Corporation	Glucagon analogs exhibiting GIP receptor activity
CN104583232B (zh)	2012-06-21	2018-04-13	印第安纳大学研究及科技有限公司	展现gip受体活性的胰高血糖素类似物
PE20150863A1 (es)	2012-06-21	2015-06-11	Univ Indiana Res & Tech Corp	Analogos de glucagon que exhiben actividad de receptor de gip
AR092873A1 (es)	2012-09-26	2015-05-06	Cadila Healthcare Ltd	Peptidos como agonistas triples de los receptores de gip, glp-1 y glugagon
UA116217C2 (uk)	2012-10-09	2018-02-26	Санофі	Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
AU2013366692B2 (en) *	2012-12-21	2017-11-23	Sanofi	Dual GLP1/GIP or trigonal GLP1/GIP/Glucagon agonists
CN105829339B (zh)	2013-11-06	2021-03-12	西兰制药公司	胰高血糖素-glp-1-gip三重激动剂化合物
TW201609798A (zh)	2013-12-13	2016-03-16	賽諾菲公司	Ｅｘｅｎｄｉｎ－４胜肽類似物
WO2015086733A1 (fr)	2013-12-13	2015-06-18	Sanofi	Agonistes mixtes des récepteurs du glp-1/glucagon
TW201609800A (zh)	2013-12-13	2016-03-16	賽諾菲公司	做為雙重ｇｌｐ－１／升糖素受體促效劑之艾塞那肽－４胜肽類似物
TW201625668A (zh) *	2014-04-07	2016-07-16	賽諾菲公司	作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625670A (zh) *	2014-04-07	2016-07-16	賽諾菲公司	衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625669A (zh)	2014-04-07	2016-07-16	賽諾菲公司	衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
WO2016198624A1 (fr) *	2015-06-12	2016-12-15	Sanofi	Dérivés d'exendine 4 utilisés en tant qu'agonistes trigonaux des récepteurs du glp-1/glucagon/gip
TW201833131A (zh)	2016-12-02	2018-09-16	法商賽諾菲公司	作為胜肽類ｇｌｐ１／升糖素／ｇｉｐ受體促效劑之新化合物
AR110300A1 (es)	2016-12-02	2019-03-13	Sanofi Sa	Compuestos como agonistas peptídicos trigonales de los receptores de glp1 / glucagón / gip

2017
- 2017-11-30 AR ARP170103362A patent/AR110300A1/es unknown
- 2017-11-30 TW TW106141759A patent/TW201833132A/zh unknown
- 2017-12-01 CN CN201780074707.9A patent/CN110023329B/zh active Active
- 2017-12-01 CR CR20190313A patent/CR20190313A/es unknown
- 2017-12-01 KR KR1020197018943A patent/KR102576872B1/ko active Active
- 2017-12-01 WO PCT/EP2017/081125 patent/WO2018100134A1/fr not_active Ceased
- 2017-12-01 EP EP17821804.6A patent/EP3548508B1/fr active Active
- 2017-12-01 US US15/829,680 patent/US10538567B2/en active Active
- 2017-12-01 EA EA201991345A patent/EA201991345A1/ru unknown
- 2017-12-01 AU AU2017367173A patent/AU2017367173B2/en active Active
- 2017-12-01 UY UY0001037506A patent/UY37506A/es unknown
- 2017-12-01 JP JP2019529535A patent/JP7100033B2/ja active Active
- 2017-12-01 CA CA3045377A patent/CA3045377A1/fr not_active Abandoned
- 2017-12-01 BR BR112019011228A patent/BR112019011228A2/pt not_active Application Discontinuation
- 2017-12-01 PE PE2019000905A patent/PE20191143A1/es unknown
- 2017-12-01 MA MA046955A patent/MA46955A/fr unknown
- 2017-12-01 MX MX2019006429A patent/MX2019006429A/es unknown
2019
- 2019-03-19 DO DO2019000068A patent/DOP2019000068A/es unknown
- 2019-05-29 IL IL266984A patent/IL266984A/en unknown
- 2019-05-30 CL CL2019001465A patent/CL2019001465A1/es unknown
- 2019-05-31 PH PH12019501216A patent/PH12019501216A1/en unknown
- 2019-06-27 CO CONC2019/0006917A patent/CO2019006917A2/es unknown
- 2019-07-01 EC ECSENADI201946893A patent/ECSP19046893A/es unknown

Also Published As

Publication number	Publication date
KR102576872B1 (ko)	2023-09-12
AR110300A1 (es)	2019-03-13
PH12019501216A1 (en)	2019-08-19
MX2019006429A (es)	2019-08-21
JP2019536796A (ja)	2019-12-19
DOP2019000068A (es)	2019-05-31
PE20191143A1 (es)	2019-09-02
CL2019001465A1 (es)	2019-10-18
EP3548508A1 (fr)	2019-10-09
KR20190085141A (ko)	2019-07-17
US10538567B2 (en)	2020-01-21
CN110023329A (zh)	2019-07-16
ECSP19046893A (es)	2019-07-31
TW201833132A (zh)	2018-09-16
BR112019011228A2 (pt)	2019-10-15
US20180155406A1 (en)	2018-06-07
CR20190313A (es)	2019-09-11
IL266984A (en)	2019-07-31
EA201991345A1 (ru)	2019-11-29
AU2017367173B2 (en)	2022-03-24
CA3045377A1 (fr)	2018-06-07
AU2017367173A1 (en)	2019-07-18
CO2019006917A2 (es)	2019-07-10
CN110023329B (zh)	2024-05-03
JP7100033B2 (ja)	2022-07-12
EP3548508B1 (fr)	2021-10-27
WO2018100134A1 (fr)	2018-06-07
UY37506A (es)	2018-06-29

Publication	Publication Date	Title
MA46955A (fr)	2021-05-19	Nouveaux composés en tant qu'agonistes récepteurs de glp1/glucagon/gip trigonal peptidique
EP3621624A4 (fr)	2021-03-24	Composés dinucléotidiques cycliques en tant qu'agonistes sting
HUE069365T2 (hu)	2025-03-28	Kondenzált gyûrûs vegyületek
MA43169A (fr)	2018-09-12	Composés hétérocycliques utilisés en tant qu'inhibiteurs de pi3k-gamma
EP3344644A4 (fr)	2019-02-27	Composés di-nucléotidiques cycliques en tant qu'agonistes de sting
MA51878A (fr)	2020-12-30	Composés d'aminothiazole en tant qu'inhibiteurs de c-kit
MA53150A (fr)	2021-05-26	Composés de benzimidazole en tant qu'inhibiteurs de c-kit
SI3523287T1 (sl)	2021-11-30	Benzo(b)tiofenske spojine kot agonisti STING
MA55194A (fr)	2022-05-04	Composés hétérocycliques en tant qu'immunomodulateurs
MA52189A (fr)	2021-02-17	Benzothiophènes et composés associés utilisés en tant qu'agonistes de sting
MA42990A (fr)	2021-03-31	Composés utiles en tant qu'immunomodulateurs
MA45377A (fr)	2019-04-24	Composés hétérocycliques en tant qu'agents antibacteriens
MA47013A (fr)	2018-08-29	Composés benzolactames utilisés en tant qu'inhibiteurs de protéine kinase
MA41551A (fr)	2017-12-26	Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
MA46091A (fr)	2019-07-10	Composés biaryles utiles en tant qu'immunomodulateurs
MA40587A (fr)	2017-06-28	Composés d'aminopyrimidinyle en tant qu'inhibiteurs de jak
DK3762380T3 (da)	2022-01-17	Phenylpyrrolidinon-formylpeptid-2-receptoragonister
MA51438A (fr)	2021-04-14	Composés hétérocycliques utilisés en tant qu'inhibiteurs de lsd1
MA52754A (fr)	2021-04-14	Composés hétérocycliques tricycliques en tant qu'activateurs de sting
MA42919A (fr)	2018-08-01	Composés bicycliques utilisés en tant qu'inhibiteurs d'atx
EP3344295A4 (fr)	2019-05-01	Récepteurs d'antigène chimère tn anti-sialyle
MA42918A (fr)	2018-08-01	Composés bicycliques utilisés en tant qu'inhibiteurs d'atx
MA45375A (fr)	2019-04-24	Composés hétérocycliques utilisés en tant qu'agents antibacteriens
HRP20190388T1 (hr)	2019-04-19	Eksendin-4 derivati kao peptidni dvostruki agonisti receptora glp-1 / glukagona
EP3523306A4 (fr)	2020-05-06	Composés spirocycliques